Contineum (CTNM) news

Contineum Therapeutics, Inc.: Jonestading raises target price to $30 from $24

Jonestading has raised its target price for Contineum Therapeutics, Inc. (CTNM) to $30 from $24, reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and market positioning. Analysts have noted improved confidence in the…

Contineum Therapeutics, Inc.: Baird cuts to neutral rating; cuts target price to $14 from $19

Contineum Therapeutics, Inc.: Leerink Partners cuts target price to $22 from $25

Leerink Partners has revised its target price for Contineum Therapeutics, Inc. (CTNM) to $22 from $25, reflecting a downward adjustment in its price forecast for the stock. This change comes amid a broader range of analyst opinions, with five Wall Street analysts currently providing ratings for the…

Contineum Therapeutics: Analyses of data including exploratory endpoints are ongoing

Contineum Therapeutics continues to analyze data from its ongoing clinical trials, with a focus on both primary and exploratory endpoints. The company has indicated that these analyses are in progress and will provide further insights into the therapeutic potential of its pipeline candidates. As…

Contineum Therapeutics, - Phase 2 Moonlight-1 trial did not meet primary efficacy endpoint

Contineum Therapeutics, Inc. (NASDAQ: CTNM) has reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307, conducted in collaboration with Johnson & Johnson, did not meet its primary efficacy endpoint for the treatment of major depressive disorder (MDD). The trial, which enrolled 107 adult…